Boston, May 6-7, 2015

Transcription

1 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller Head of Bayer HealthCare Global Development Boston, May 6-7, 2015 Page 1 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015 Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Page 2 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015

2 Leading Positions in Key Healthcare Markets by Segment % 21% 60% 12% 7% HealthCare 19,975m Consumer Health Rx Pharma 12,052m Leading positions in key therapeutic categories Consumer Care 4,245m Global #2 in OTC-pharmaceuticals Medical Care 2,360m #1 in fluid injection systems, #1 in contrast media, #3/4 in blood glucose meters Animal Health 1,318m Global #5, #2 in parasiticides Page 3 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015 One of the Fastest-Growing Global Pharma Companies billion; % Fx & portfolio adj. +1% % +9% 12.1 Maximize the value of launch +4% products Drive commercial excellence in marketing and sales Plans for continued growth Advance early and mid-stage pipeline Achieve phase III readiness for key phase II assets by mid-2016 Explore opportunities for partnerships, open innovation and bolt-on acquisitions Page 4 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015

3 Q Pharma: Launch Products Drove Growth in million, % yoy, () = Fx & portf. adj. Earnings before special items, in million, % yoy Launch products EBITDA EBIT % % Pharmaceuticals 3,200m; +15% (+7%) Q1 14 Q1 15 Q1 14 Q1 15 Page 5 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015 HealthCare: 2015 Financial Outlook Raised Mainly Due to Fx % Fx & portfolio adj. HealthCare * Mid-single-digit % increase EBITDA before special items* Low-twenties % increase (previously: mid-teens %) Pharma Consumer Health Mid-to-high-single-digit % increase Launch product sales: increase to over 4bn (previously: increase towards 4bn) Mid-single-digit % increase Mid-teens % increase (previously: low-teens % increase) Mid-thirties % increase (previously: mid- to high-twenties % increase) Page 6 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015 *Assuming spot Fx rates end Q1, 2014 for FY 15 Outlook depends on specific planning assumptions as detailed in the Annual Report

4 Strategic Priorities for Pharma Maximize the value of recently launched products Achieve phase III readiness for key phase II assets by mid-2016 Advance early and mid-stage pipeline Page 7 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015 Pharma Launch Products Drive Growth: Combined Peak Potential of 7.5bn Collective billion 1Q 2015 Individual million, % yoy Fx adj. Over % % Total 898bn % e +55% Page 8 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015

5 Xarelto: The Leading Novel Oral Anticoagulant in million, % yoy Fx adj % Q Achievements Continued dynamic growth Clear market share lead among novel oral anticoagulants: Xarelto: ~32% Pradaxa: ~13% Eliquis: ~12% (Global anticoagulant market, sales share, Jan. 2015) >11 million patients treated to date Comprehensive global life-cyclemanagement program in place Label expansion: Recommended for cardioversion in Afib-patients in Europe Page 9 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015 Eylea: Label Expansion Expected to Support Growth in million, % yoy Fx adj. 759 Achievements Strong growth driven by continued roll-out activities Label expansion in 2H 2014 including: DME Europe & Japan mcnv Japan % 253 Positive data from NIH/DRCR sponsored study comparing Eylea, Avastin and Lucentis in DME Q Page 10 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller Agreement with Regeneron to develop a coformulation of Eylea and a PDGFR-β antibody for treatment of wamd 1) NEJM February 18, 2015 DOI: /NEJMoa DME: Diabetic macular edema, BRVO: Branched retinal vein occlusion, mcnv: Myopic choroidal neovascularization, wamd: Wet age-related macula degeneration NIH: National Institutes of Health, DCRC: Diabetic Retinopathy Clincial Research Network, PDGFR: Platelet derived growth factor receptor

6 Xofigo: Significant Growth Expected in million, % yoy Fx adj. Achievements 157 Launch activities ongoing Approved in 42 countries 1 Launched in 30 countries % 54 Targeting > 300m sales in 2015 Life-cycle management program targeting label expansions in CRPC and additional cancer indications underway Q Page 11 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015 CRPC: Castration resistant prostate cancer 1) As of April 2015 Stivarga: Leading 3L+ Treatment of Metastatic Colorectal Cancer in million, % yoy Fx adj Achievements Most prescribed agent in 3rd-line plus treatment of mcrc in the US and in Japan Roll-out activities in mcrc and GIST continuing + 14 % 71 Targeting increased use in 3Ltreatment of mcrc ~45,000 patients treated to date Q mcrc: Metastatic colorectal cancer; GIST: Gastrointestinal stromal tumor Page 12 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015

7 Adempas: Encouraging Early Launch Experience 2014 in million, % yoy Fx adj Achievements Launched in PAH and CTEPH in first countries PAH CTEPH Approved Launched ~3,600 patients treated to date 2 9 Life-cycle management trials in systemic sclerosis, cystic fibrosis and in PH associated with idiopathic interstitial pneumonias initiated 2014 Q Agreement with Merck & Co. for joint development and commercialization of sgc-modulators in place Page 13 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, ) as of January 2015; 2) as of January 2015, PH: Pulmonary hypertension PAH: Pulmonary arterial hypertension, CTEPH: Chronic thrombo-embolic pulmonary hypertension, sgc: Soluble guanylate cyclase Incremental R&D-Investments To Progress Pharma Pipeline Life-cycle Management Projects from Midand Late-stage Pipeline Opportunities in Research and Early Pipeline Xarelto (Rivaroxaban) Eylea (Aflibercept) Xofigo (Radium-223 dichloride) Stivarga (Regorafenib) Adempas (Riociguat) Finerenone Copanlisib Molidustat Vericiguat Vilaprisan Damoctocog alfa pegol ODM-201 Cardiology Hematology Oncology Gynecological Therapies Ophthalmology Inflammation Page 14 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015

8 Rivaroxaban - Comprehensive Life-cycle Management Program Underway Indication Trial End date* Areas with patients at risk of arterial thromboembolism: Chronic heart failure and significant coronary artery disease COMMANDER-HF Apr 2017 Major cardiovascular events in coronary or peripheral artery disease COMPASS Jan 2018 Embolic stroke of undetermined source (ESUS) NAVIGATE ESUS Jan 2018 Peripheral artery disease undergoing peripheral artery interventions VOYAGER PAD Yet to start Acute coronary syndrome (ACS) GEMINI ACS 1 Jan 2017 (PH II) Specific AF-patient populations: Non-valvular atrial fibrillation + catheder ablation VENTURE-AF completed Non-valvular atrial fibrillation + cardioversion X-VeRT published Non-valvular atrial fibrillation + left atrial/left atrial appendage thrombus X-TRA completed Non-valvular atrial fibrillation + percutaneous coronary intervention PIONEER AF-PCI Aug 2016 DVT and PE in specific patient populations: Long-term prevention of symptomatic recurrent DVT and/or PE EINSTEIN CHOICE Nov 2016 Symptomatic DVT and/or PE due to concurrent medical illness MARINER Feb 2017 Treatment and sec. prevention of DVT and/or PE in pediatric patients EINSTEIN JUNIOR Nov 2018 Page 15 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller Rivaroxaban is being developed in cooperation with Janssen Research & Development LLC, a Johnson & Johnson company *) Primary trial completion dates as of April 28, 2015 Committed to Improving Thrombosis Management Clinical Studies and Registries Registries N 97,000 Phase IV/NIS N 47,000 Phase IIIb N 2,400 Phase II/III N 51,000 Completed Over 275,000 patients are expected to be included in both clinical trials and real world settings. Page 16 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015

9 Regorafenib Potential for Significant Advances in Treating wamd Current Standard intravitreal injection Today s standard of care is administered by injection into the eye Project Goal topical treatment (drops) as additional option Eye drops could reduce efforts, costs, logistics and would be more convenient Regorafenib inhibits VEGF receptor signaling, a well established principle to treat wamd Regorafenib eye drops may offer topical treatment of wamd - targeting superior convenience but non-inferior efficacy Phase I completed Phase IIa/b initiated Comparator: Lucentis Target enrollment: N=540 patients Completion expected April 2016 wamd: Wet age-related macular degeneration; Primary completion dates Page 17 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015 as published at clinicaltrials.gov, status February, 2015 Mid- and Late-Stage Pharma Pipeline Progressing Current Timelines Damoctocog alfa pegol Hemophilia A 2014 Phase III (pediatric) ODM-201 CRPC Copanlisib Cancer; NHL Finerenone Diabetic nephropathy Worsening CHF Vericiguat Worsening CHF ref Worsening CHF pef Phase IIa Phase Phase IIb IIb Phase IIb Phase IIb Phase IIb Phase III Phase III reported PH III decision PH III decision PH III decision Molidustat Renal anemia Vilaprisan Uterine fibroids Endometriosis Phase IIb Phase IIb Phase IIa PH III decision PH III decision CHF: Chronic heart failure; CRPC: Castration-resistant prostate cancer; Page 18 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015NHL: Non-Hodgkin s lymphoma; r/pef: Reduced/preserved ejection fraction

10 Attractive Early Pipeline Projects* Project Mechanism Target Indication Status BAY Non-nucleosidic partial A1 receptor Worsening chronic heart failure Phase IIa agonist BAY FXIa antibody Anti-coagulation therapy Phase I BAY Chymase inhibitor Cardiovascular diseases Phase I BAY Anti-TFPI antibody Hemophilia Phase I Plasminogen- Inhibitor Inhibition of fibrinolysis Various bleeding disorders incl. hemophilia Phase I start mid 2015e Roniciclib Pan-CDK-inhibitor Small-cell lung cancer Phase II Anetumab ravtansine Mesothelin antibody-drugconjugate Solid tumors Phase II BAY FGFR2 antibody Solid tumors Phase I BAY PSMA-BiTE Prostate cancer Phase I BAY AKR1C3 inhibitor Endometriosis Phase I Page 19 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015 * Selection only Pharma Well-positioned for Growth Attractive growth profile: Aspire for 7% CAGR ( ) Pharma launch products with combined peak sales potential of 7.5bn Comprehensive life-cycle management program to fully exploit potential of launch products Mid- and late-stage pharma pipeline progressing - Expect increasing visibility in 2015 / 2016 Improving margin: Aspire to generate EBITDA before special items margin between 32 and 34% by 2017 Page 20 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015

11 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller Head of Bayer HealthCare Global Development Boston, May 6-7, 2015 Page 21 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May 6-7, 2015